Drs. Hornstein, Brown, and Grewal discuss how Claudin 18.2 has quickly become an important actionable biomarker in upper GI cancers, with zolbetuximab now entering frontline treatment for selected HER2-negative, microsatellite-stable patients. They review the key phase 3 data supporting its use, while emphasizing that the major challenge in practice is managing the significant nausea and […]
This episode focuses on the rapidly evolving treatment landscape for HER2-positive upper GI cancers, with major attention on MATTERHORN, DESTINY-Gastric04, and Horizon-GEA-01. Drs. Hornstein, Brown, and Grewal highlight how perioperative immunotherapy is changing care in localized disease, while trastuzumab deruxtecan is establishing itself in the second-line setting and zanidatamab-based combinations appear poised to move into […]
Early ASCO GI 2026 data spotlight major advances in HER2-positive and CLDN18.2-expressing upper GI cancers, with bispecific HER2 targeting showing meaningful progression-free and overall survival improvements over historical standards. Drs. Hornstein, Brown, and Grewal break down why agents like Zanidatamab may reshape frontline therapy, while also addressing limitations of control arms and real-world toxicity considerations. […]